HFU 2024 Reg

Learning Objectives

MEETING THEME

Healing Hearts: Confronting Comorbidities and Heart Failure

 

OVERALL CONGRESS LEARNING OBJECTIVES

After attending this congress, participants will be able to:

  1. Employ novel treatment approaches and interdisciplinary collaboration to improve outcomes in patients living with heart failure. (Medical Expert, Scholar, Collaborator)
  2. Optimize therapies in individuals with heart failure and comorbidities. (Medical Expert, Communicator, Professional)
  3. Diagnose patients living with heart failure with an aim to deliver holistic care. (Medical Expert, Health Advocate, Professional) 

 

SESSION SPECIFIC LEARNING OBJECTIVES 

PLENARY 1: Healing Hearts

A Call to Action:  Gaps and Access to HF Care in Canada 

Our motivation is that after attending this presentation, participants will be able to:

  1. Recognize gaps in quality of care and access to care for HF in Canada (Medical Expert, Leader)
  2. Analyze potential sources of disparities in HF care access and quality (Scholar, Collaborator)
  3. Propose and implement solutions for improvement (Health advocate)

Culturally Inclusive and Remote HF Care for Indigenous Persons

Our motivation is that after attending this presentation, participants will be able to:

  1. Examine the needs of Indigenous population to access local and culturally inclusive HF care (Health Advocate, Scholar)
  2. Discuss the importance of patient and community satisfaction while ensuring improvement in morbidity and mortality (Health Advocate, Communicator)
  3. Identify and develop key changes to provide inclusive and accessible care for the Indigenous persons (Leader, Health Advocate)

Language Matters and Resiliency Matters in HF Care

Our motivation is that after attending this presentation, participants will be able to:

  1. Use positive and understandable language to communicate and engage with patients and care partners (Communicator, Collaborator)
  2. Acknowledge the longitudinal journey and transitions when caring for HF patients (Communicator)
  3. Apply methods to improve resiliency in patients and in health care practitioners (Communicator, Collaborator, Leader)

Implementation Across a Continuum of EF

Our motivation is that after attending this presentation, participants will be able to:

  1. Recommend therapies for HF patients across the LVEF continuum (Medical Expert)
  2. Review evolving data to support implementation of therapies for patients living with heart failure (Scholar)
  3. Recognize system and patient-level barriers to implementation (Leader, Communicator, Collaborator)

 

PLENARY 2: Clinical Pearls and Conundrums in HF Clinical Care

Great HF Papers of the Past Year

Our motivation is that after attending this presentation, participants will be able to:

  1. Highlight some of the most provocative and impactful research in heart failure and cardiomyopathies over the past year (Medical Expert)
  2. Discuss how the results of these trials could change the way that we currently manage patients with heart failure and/or cardiomyopathies (Medical Expert, Health Advocate, Leader)

ABC’s of De-congesting “Congestive” Heart Failure

Our motivation is that after attending this presentation, participants will be able to:

  1. Provide an overview of medical therapies that can be used to decongest patients with acute heart failure (Medical Expert, Scholar)
  2. Define diuretic resistance (Scholar)
  3. Describe strategies that can be used to decongest patients who have diuretic resistance (Medical Expert, Health Advocate)​​​​​​

A device first strategy to Optimize GDMT + Outcomes in HF

Our motivation is that after attending this presentation, participants will be able to:

  1. Review the latest advances in devices that can be used to manage patients with heart failure (Scholar)
  2. Describe how these devices can be used to optimize GDMT and outcomes in heart failure (Medical Expert, Leader)

DEBATE: Is Canada ready for Implantable Hemodynamic Monitoring

Our motivation is that after attending this presentation, participants will be able to:

  1. Provide an overview of trials that focus on the use of implantable hemodynamic monitoring in patients with heart failure (Scholar)
  2. Highlight benefits of using implantable hemodynamic monitoring in patients with heart failure (Medical Expert, Scholar)
  3. Identify potential barriers to widespread utilization of implantable hemodynamic monitoring in patients with heart failure (Health Advocate, Leader)
    ​​​​​

PLENARY 3: (English): The Rainbow Connection: Confronting Comorbidities and Cardiomyopathies

Heart-Lung Connection

Our motivation is that after attending this presentation, participants will be able to:

  1. Recognize the interaction of heart failure with common respiratory comorbidities including COPD (Scholar)
  2. Discuss the diagnosis and treatment of pulmonary hypertension (Medical Expert, Communicator, Collaborator)
  3. Identify opportunities to reduce cardiorespiratory risk (Leader, Health Advocate)

Heart-Kidney-Metabolic Connection

Our motivation is that after attending this presentation, participants will be able to:

  1. Discuss the overlapping role of SGLT2i and GLP1 RA in HF, CKD and obesity (Scholar, Collaborator)
  2. Review the highlights of recent cardio-kidney-metabolic guidelines (Scholar, Medical Expert)

Heart-Cancer Connection

Our motivation is that after attending this presentation, participants will be able to:

  1. Review recent recommendations for cancer treatment-related cardiac toxicity screening for the most common clinical scenarios (Scholar)
  2. Adapt long-term follow-up for cancer survivors with or at risk of developing cardiotoxicities (Leader) 
  3. Recognize the cardiac “emergencies” secondary to cancer treatment (such as immune checkpoint inhibitors, myocarditis and HF in patients receiving anthracycline and/or HER2 inhibitors) (Medical Expert)

ESC Guidelines for the Management of Cardiomyopathies

Our motivation is that after attending this presentation, participants will be able to:

  1. Review the key aspects in the evaluation and management of cardiomyopathies (Medical Expert)
  2. Describe the evidence to support new therapies for hypertrophic cardiomyopathy (Scholar)

 

PLENARY 3: (French Concurrent): La connexion arc-en-ciel : faire face aux comorbidités et aux cardiomyopathies.

Connexion cœur-poumon

Notre motivation est qu'après avoir assisté à cette présentation, les participants seront en mesure de :

  1. Reconnaitre l’interaction entre l’insuffisance cardiaque et les maladies concomitantes respiratoires courantes, notamment la MPOC (Érudit)
  2. Discuter du diagnostic et du traitement de l’hypertension pulmonaire (Collaborateur, Expert médical)
  3. Identifier les opportunités afin de réduire le risque d’un arrêt cardiorespiratoire (Promoteur de la santé)

Connexions cœur-rein-métabolisme

Notre motivation est qu'après avoir assisté à cette présentation, les participants seront en mesure de :

  1. Discuter du rôle complémentaire de la SGLT2 et du GLP-1 par rapport à l’IC, les MRC et l’obésité (Collaborateur)
  2. Examiner les faits marquants issus des plus récentes lignes directrices en matière de cardio-rein-métabolisme (Expert médical, Érudit)

Connexion cœur-cancer

Notre motivation est qu'après avoir assisté à cette présentation, les participants seront en mesure de :

  1. Examiner les recommandations récentes en matière de dépistage de la cardiotoxicité liée au traitement du cancer dans les scénarios cliniques les plus courants (Érudit)
  2. Adapter un suivi à long-terme pour les survivants du cancer avec un risque ou à risque de développer des cardiotoxicités (Leader) 
  3. Reconnaitre les “urgences” cardiaques secondaires au traitement du cancer (tels que les inhibiteurs du point de contrôle immunitaire, la myocardie et l’insuffisance cardiaque chez les patients recevant de l’anthracycline et/ou des inhibiteurs de la HER2) (Expert médical)

Lignes directrices de la SEC pour la prise en charge des cardiomyopathies

Notre motivation est qu'après avoir assisté à cette présentation, les participants seront en mesure de :

  1. Examiner les aspects clés dans l’évaluation et la prise en charge des cardiomyopathies (Expert médical)
  2. Décrire les arguments en faveur des nouvelles thérapies pour la cardiomyopathie hypertrophique (Collaborateur, Érudit)

 

PLENARY 4: Hit Me with Your Best Shock

Shock Pathways and Regional Shock Programs-Canada experience

Our motivation is that after attending this presentation, participants will be able to:

  1. Summarize existing Shock Programs and experience in Canada (Medical Expert, Leader)
  2. Contrast the specific needs for urban versus regional programs in Canada (Health Advocate)
  3. Recognize key predictors for both individual patient and program success (Scholar)

Shock Pathways and Regional Shock Programs-USA experience

Our motivation is that after attending this presentation, participants will be able to:

  1. Summarize existing Shock Programs and experience in USA (Medical Expert, Leader)
  2. Contrast the specific needs for urban versus regional programs in USA (Health Advocate)
  3. Recognize key predictors for both individual patient and program success (Scholar)

Medical Management of Patients on Durable MCS Support

Our motivation is that after attending this presentation, participants will be able to:

  1. Interpret the hemodynamic status and impact of continuous flow of patients on durable MCS (Medical Expert, Scholar)
  2. Diagnose common medical situations in patients with durable MCS (Medical Expert)
  3. Apply treatment plans adapted for the durable MCS supported patient (Medical Expert, Communicator)

DEBATE:  It’s Time for Universal DT in Canada

Our motivation is that after attending this presentation, participants will be able to:

  1. Compare the patient’s outcomes and satisfaction with and without DT MCS (Medical Expert, Communicator)
  2. Contrast the difference between provinces in access to DT MCS (Health Advocate, Scholar)
  3. Critique the impact of DT MCS on global health care in Canada (Health Advocate)

 

WORKSHOP OBJECTIVES:

Coming soon.

 

Follow @CanHFSociety Along on Twitter

#HFUpdate